Amyloid pet in primary progressive aphasia: case series and systematic review of the literature
- 661 Downloads
Primary progressive aphasia (PPA) is considered a heterogeneous syndrome, with different clinical subtypes and neuropathological causes. Novel PET biomarkers may help to predict the underlying neuropathology, but many aspects remain unclear. We studied the relationship between amyloid PET and PPA variant in a clinical series of PPA patients. A systematic review of the literature was performed. Patients with PPA were assessed over a 2-year period and classified based on language testing and the International Consensus Criteria as non-fluent/agrammatic (nfvPPA), semantic (svPPA), logopenic variant (lvPPA) or as unclassifiable (ucPPA). All patients underwent a Florbetapir (18-F) PET scan and images were analysed by two nuclear medicine physicians, using a previously validated reading method. Relevant studies published between January 2004 and January 2016 were identified by searching Medline and Web of Science databases. Twenty-four PPA patients were included (13 women, mean age 68.8, SD 8.3 years; range 54–83). Overall, 13/24 were amyloid positive: 0/2 (0%) nfvPPA, 0/4 (0%) svPPA, 10/14 (71.4%) lvPPA and 3/4 (75%) ucPPA (p = 0.028). The systematic review identified seven relevant studies, six including all PPA variants and one only lvPPA. Pooling all studies together, amyloid PET positivity was 122/224 (54.5%) for PPA, 14/52 (26.9%) for nfvPPA, 6/47 (12.8%) for svPPA, 101/119 for lvPPA (84.9%) and 12/22 (54.5%) for ucPPA. Amyloid PET may help to identify the underlying neuropathology in PPA. It could be especially useful in ucPPA, because in these cases it is more difficult to predict pathology. ucPPA is frequently associated with amyloid pathology.
KeywordsPET Amyloid Primary progressive aphasia PIB Florbetapir
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
The Ethics Committee for medical research of Hospital Universitario Doce de Octubre has approved this study.
Drs. Llamas-Velasco (CM13/00079) and González-Sánchez (CM15/00222) have been supported by a Rio Hortega grant for clinical research (Instituto de Salud Carlos III, Spain).
- 7.Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC (2006) Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 129:1385–1398CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Grossman M, Wood EM, Moore P, Neumann M, Kwong L, Forman MS, Clark CM, McCluskey LF, Miller BL, Lee VM, Trojanowski JQ (2007) TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol 64:1449–1454CrossRefPubMedGoogle Scholar
- 12.McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Martersteck A, Murphy C, Rademaker A, Wieneke C, Weintraub S, Chen K, Mesulam MM, Rogalski E, Initiative Alzheimer’s Disease Neuroimaging (2016) Alzheimer’s disease neuroimaging initiative. Is in vivo amyloid distribution asymmetric in primary progressive aphasia? Ann Neurol 79:496–501CrossRefPubMedGoogle Scholar
- 23.Botha H, Duffy JR, Whitwell JL, Strand EA, Machulda MM, Schwarz CG, Reid RI, Spychalla AJ, Senjem ML, Jones DT, Lowe V, Jack CR, Josephs KA (2015) Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex 69:220–236CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Whitwell JL, Duffy JR, Strand EA, Machulda MM, Senjem ML, Schwarz CG, Reid R, Baker MC, Perkerson RB, Lowe VJ, Rademakers R, Jack CR Jr, Josephs KA (2015) Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain Lang 142:45–53CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD (2013) Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain 136:844–858CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Whitwell JL, Lowe VJ, Duffy JR, Strand EA, Machulda MM, Kantarci K, Wille SM, Senjem ML, Murphy MC, Gunter JL, Jr Jack CR, Josephs KA (2013) Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. J Neurol Neurosurg Psychiatry 84:1357–1364CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Gil-Navarro S, Lladó A, Rami L, Castellví M, Bosch B, Bargalló N, Lomeña F, Reñé R, Montagut N, Antonell A, Molinuevo JL, Sánchez-Valle R (2013) Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. Dement Geriatr Cogn Disord 35:106–117CrossRefPubMedGoogle Scholar